Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADIUVO: Adjuvant Mitotane in Low-Intermediate Risk Adrenocortical Carcinoma
NCT00777244Phase 3Unknown
- Sponsor
- University of Turin
- Start
- Apr 2008
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of mitotane in adrenocortical carcinoma (ACC) (2 arms), sponsored by University of Turin. Primary endpoint: Disease-Free Survival. Status: unknown.
02
Drugs
mitotane
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00777244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777244.